Stellar Biotechnologies reported earnings of $70,000 for its second quarter ended June 30 and narrowed its net losses 5 percent to $1.16 million. The company manufactures proteins derived from marine mollusks for use in immunotherapies out of Port Hueneme. It reported that expenses decreased for the quarter during which it raised $8.8 million, giving it…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
